Biotech Values

[hirogen]

No news but there have been positive blogs about the new 1st quarter.

From what I've seen of the positive blogs, most are based on -
1) comparison to KERX mgmt's prior expectations of a 4Q11 release of results (which I have been unable to resolve the basis for said expectations)
2) survival functions that use a fixed survival time or a normal distribution with arbitrary std dev
3) assumption of what the control arm MST is (typically favorable for significant PCAP survival benefit)